Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash & Current Investments (2019 - 2025)

Historic Cash & Current Investments for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $693.5 million.

  • Keros Therapeutics' Cash & Current Investments rose 3067.51% to $693.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $693.5 million, marking a year-over-year increase of 3067.51%. This contributed to the annual value of $559.9 million for FY2024, which is 6908.84% up from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Cash & Current Investments is $693.5 million, which was up 3067.51% from $690.2 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Cash & Current Investments ranged from a high of $720.5 million in Q1 2025 and a low of $215.6 million during Q2 2022
  • Moreover, its 5-year median value for Cash & Current Investments was $322.0 million (2023), whereas its average is $381.2 million.
  • Examining YoY changes over the last 5 years, Keros Therapeutics' Cash & Current Investments showed a top increase of 36810.78% in 2021 and a maximum decrease of 1347.77% in 2021.
  • Keros Therapeutics' Cash & Current Investments (Quarter) stood at $230.0 million in 2021, then increased by 21.3% to $279.0 million in 2022, then increased by 18.67% to $331.1 million in 2023, then soared by 69.09% to $559.9 million in 2024, then increased by 23.85% to $693.5 million in 2025.
  • Its last three reported values are $693.5 million in Q3 2025, $690.2 million for Q2 2025, and $720.5 million during Q1 2025.